New trials and results in systemic treatment of HCC
María Reig'Correspondence information about the author María ReigEmail the author María Reig
, Leonardo Gomes da Fonseca
, Sandrine Faivre'Correspondence information about the author Sandrine FaivreEmail the author Sandrine Faivre
PlumX Metrics
DOI: https://doi.org/10.1016/j.jhep.2018.03.028 |
Article Outline
Systemic treatments approved for advanced hepatocellular carcinoma
Recent phase III trials for first-line therapy
Recent phase III trials for second-line therapy
Other ongoing/recent trials
Conclusions
Financial support
Conflict of interest
Supplementary data
References
Summary
The design of prospective trials in hepatocellular carcinoma is a true challenge because the underlying condition of the liver, upon drug exposure, could interact with the specific course of carcinoma and influence overall outcome. The information generated by basic and clinical researchers provides the rationale for improving the prognosis of this complex disease. However, an additional challenge is interpreting emerging data in real time in order to integrate them into the design of further trials. Analysing recent results in detail may contribute to improving trial design and analysis, expediting the translation of a novel agent’s potential benefit, assessed in prospective interventions, to clinical practice. This review summarises the data already known and discusses newly available results, along with ongoing systemic trials in hepatocellular carcinoma treatment.
全新治疗HCC的新试验和结果
MaríaReig'Correspondence相关信息作者MaríaReigEmail作者MaríaReig
，Leonardo Gomes da Fonseca
，Sandrine Faivre'的相关信息，作者Sandrine FaivreEmail的作者Sandrine Faivre
PlumX度量标准
DOI：https：//doi.org/10.1016/j.jhep.2018.03.028 |